Core Viewpoint - The stock of Giant Bio (02367) has experienced a decline of over 6%, currently trading at 39.8 HKD, with a transaction volume of 513 million HKD, following the approval of its medical device product, a recombinant type I α1 collagen lyophilized fiber [1] Group 1: Company Developments - Giant Bio's "recombinant type I α1 collagen lyophilized fiber" has received approval as a Class III medical device, marking it as China's first recombinant type I natural sequence collagen facial injection product [1] - Huatai Securities maintains its profit forecast for the company, projecting a net profit for 2025-2027 [1] Group 2: Market Performance - CooBeauty's online sales performance during the first phase of the Double Eleven shopping festival has been relatively weak, with an estimated 10% year-on-year decline in online revenue for the second half of the year, leading to an overall online revenue growth rate of approximately 5% for the year [1] - In contrast, Collyre's online revenue is expected to achieve a high growth rate of about 40% for the year, while offline business is anticipated to maintain steady growth [1] - The revenue growth forecast for the company is expected to slow down to 12% by 2025 [1]

Core Viewpoint - The stock of Giant Bio (02367) has experienced a decline of over 6%, currently trading at 39.8 HKD, with a transaction volume of 513 million HKD, following the approval of its medical device product [1] Group 1: Company Developments - Giant Bio's "Recombinant Type I α1 Collagen Lyophilized Fiber" has received approval as a Class III medical device, marking it as China's first recombinant Type I natural sequence collagen facial injection product [1] - Huatai Securities maintains its profit forecast for Giant Bio, projecting a net profit for the parent company in 2025-2027 [1] Group 2: Market Performance - Zheshang International reports that the online sales performance of Kefu Beauty during the first phase of the Double Eleven shopping festival was relatively weak, estimating a 10% year-on-year decline in online revenue for the second half of the year [1] - Keli Jin is expected to achieve approximately 40% high growth in annual online revenue, while offline business is projected to maintain steady growth [1] - The revenue growth forecast for the company is expected to slow down to 12% by 2025 [1]

Investment Rating - The industry rating is "Overweight" (maintained) [6] Core Insights - The report highlights that the beauty and personal care industry has shown a relative return of -2.84% over the past month, -13.54% over the past three months, and -14.02% over the past year compared to the CSI 300 index [3] - The report notes that the newly approved recombinant type I collagen products by Juzhi Biotech are expected to enhance market competition, with various specifications available [6] - The report emphasizes the strong performance of brands like Han Shu and Proya during the "Double 11" shopping festival, indicating robust consumer demand [6] Summary by Sections Industry Performance - The beauty and personal care sector has experienced a relative return of -2.84% in the last month, -13.54% in the last three months, and -14.02% in the last year compared to the CSI 300 index [3] Product Developments - Juzhi Biotech's recombinant type I collagen has been approved, with product specifications ranging from 10mg to 24mg per bottle, primarily used for facial dermal filling to correct dynamic wrinkles [6] - The report mentions that the recombinant collagen market is seeing new entrants, with Juzhi Biotech and Jinbo Biotech being key players [6] Market Trends - Data from Q3 2025 shows that the GMV for the beauty category on Douyin grew by 19.69% year-on-year, with Han Shu leading with over 500 million in GMV [6] - The report indicates that Proya has consistently ranked first in the Tmall beauty category for three consecutive years, with expectations to maintain this position in 2025 [6] Investment Recommendations - The report suggests monitoring Juzhi Biotech's marketing strategies and sales performance for its new collagen products [6] - It recommends focusing on leading domestic skincare companies like Proya and Shanghai Jahwa, as well as other listed companies in the collagen sector [6]

Core Viewpoint - CICC maintains the profit forecast for Giant Bio (02367) for 2025-2026, with the current stock price corresponding to a P/E of 16/13x for those years, and sets a target price of HKD 70, indicating a potential upside of 68% based on the approval of medical beauty products and the recovery of the cosmetics business [1] Company Status - On October 23, Giant Bio announced that its "Recombinant Type I α1 Collagen Lyophilized Fiber" medical device has been approved, marking it as China's first recombinant Type I natural sequence collagen facial injection product [2][3] Product Approval and Market Potential - The approved product is indicated for facial tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet. The market for recombinant collagen injectables is still considered a blue ocean, and the company is expected to benefit from first-mover advantages, with potential revenue from this product projected to reach around RMB 1 billion in the long term [3] Commercialization Preparation - The company has made substantial preparations for commercialization, including team building and initial communication with doctors and institutions. As of the first half of 2025, it has covered approximately 1,700 public hospitals and 3,000 private hospitals and medical beauty clinics, leveraging its existing sales experience and brand operation capabilities to enhance product visibility and market promotion [4] Future Pipeline and Growth Opportunities - The company has a rich pipeline of future products, including non-crosslinked hydrating products currently in the registration phase, crosslinked neck wrinkle products that have received priority review status, and crosslinked nasolabial fold products progressing smoothly. The approval of the first medical beauty product validates the company's technological leadership and safety, with further pipeline developments expected to broaden the growth trajectory. Additionally, the cosmetics business is anticipated to improve gradually with the recovery of promotional activities [5]

Core Viewpoint - CICC maintains the profit forecast for Giant Bio (02367) for 2025-2026, with the current stock price corresponding to a P/E of 16x for 2025 and 13x for 2026. The target price is set at HKD 70, reflecting a potential upside of 68% based on the approval of medical beauty products and the recovery of the cosmetics business [1]. Company Status - On October 23, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen Lyophilized Fiber" as a Class III medical device, marking it as China's first recombinant Type I natural sequence collagen facial injection product. This approval is expected to enhance the company's long-term growth potential in the medical beauty sector [2][3]. Product Approval and Market Potential - The approved recombinant collagen product is indicated for facial tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet. The medical beauty injection market is still considered a blue ocean, and the company is expected to benefit from first-mover advantages, with projected revenues potentially reaching CNY 1 billion in the long term [3]. Commercialization Readiness - The company has made substantial preparations for commercialization, including team building and initial communications with doctors and institutions. As of the first half of 2025, the company has established a presence in approximately 1,700 public hospitals and 3,000 private hospitals and medical beauty clinics, leveraging its existing sales experience to enhance product visibility and market promotion [4]. Future Pipeline and Growth Opportunities - The company has a rich pipeline of future products, including non-crosslinked hydrating products currently under registration, crosslinked neck wrinkle products with priority review status, and crosslinked nasolabial fold products progressing smoothly. The approval of the first medical beauty product validates the company's technological leadership and safety, with further product launches expected to broaden its growth trajectory. Additionally, the cosmetics business is anticipated to improve gradually with the recovery of promotional activities [5].

Macro Strategy - The "Innovation Bull" market is entering a consolidation phase, driven by a positive cycle of capital pricing and industrial implementation under policy guidance [1][13] - Current macro policies are still being implemented, and the "KOT" valuation system is gradually improving, with medium to long-term funds expected to enter the market annually [1][13] - Market liquidity and valuations have improved, with public fund net values exceeding 1, indicating potential for accelerated fund issuance [1][13] - The market is likely to extend towards technology sectors such as computing power, chips, robotics, and energy storage as the "Innovation Bull" evolves into a comprehensive bull market [1][13] Fixed Income - The report discusses how to identify arbitrage opportunities in the Sci-Tech Bond ETF component bonds, focusing on bonds with an implied rating of AA+ or higher and smaller issuance sizes [2][14] - The report emphasizes the importance of liquidity and credit quality in selecting bonds for inclusion in the ETF, with a preference for bonds issued by central state-owned enterprises [2][14] - The report highlights the potential for price appreciation of bonds that are included in the ETF due to passive fund inflows [2][15] Industry Analysis - The report identifies the "brain" as a key component in the development of embodied intelligence, with various companies exploring different technological paths [4][16] - The embodied intelligence market is expected to grow rapidly, with significant investment in brain technology, which is seen as the most critical and challenging aspect of the market [4][16] - Key players in the market include companies like 品茗科技, 银河通用, and Tesla, among others, with a recommendation to focus on these related stocks [4][16] Company Recommendations - 派能科技 (688063) is projected to recover from impairment and exchange rate impacts, with expected net profits of 1.0/5.0/7.2 billion yuan for 2025-2027, reflecting significant growth [5][17] - 巨子生物 (02367.HK) has received approval for its first type I recombinant collagen product, which is expected to drive growth in the medical beauty sector, with projected net profits of 25.66/32.14/40.46 billion yuan for 2025-2027 [6][18] - 联合动力 (301656) reported a slight decline in net profit but maintains a positive long-term outlook, with expected net profits of 11.3/16.8/25.8 billion yuan for 2025-2027 [7][21] - 杰瑞股份 (002353) continues to show growth potential with projected net profits of 30/35/40 billion yuan for 2025-2027, despite short-term delivery challenges [8][22]

Core Insights - The top three stocks with net inflows from southbound funds are Yingfu Fund (02800) with 1.995 billion, China National Offshore Oil Corporation (00883) with 1.424 billion, and SMIC (00981) with 636 million [1][2] - The top three stocks with net outflows are Hua Hong Semiconductor (01347) with -299 million, GigaDevice Semiconductor (02367) with -179 million, and Zhaojin Mining (01818) with -162 million [1][2] - In terms of net inflow ratios, GX Hengsheng Technology (02837) leads with 89.26%, followed by Far East Horizon (03360) at 80.25%, and Tuhu-W (09690) at 67.29% [1][2] - The stocks with the highest net outflow ratios include Huadian International Power (01071) at -74.23%, CIMC Enric (03899) at -63.04%, and Weilu Group (01196) at -57.66% [1][2] Net Inflow Rankings - Yingfu Fund (02800) recorded a net inflow of 1.995 billion, representing a 15.63% increase, with a closing price of 26.420 [2] - China National Offshore Oil Corporation (00883) saw a net inflow of 1.424 billion, with a net inflow ratio of 46.50% and a closing price of 19.500 [2] - SMIC (00981) had a net inflow of 636 million, with a net inflow ratio of 10.38% and a closing price of 74.850 [2] Net Outflow Rankings - Hua Hong Semiconductor (01347) experienced a net outflow of -299 million, with a net outflow ratio of -9.94% and a closing price of 75.950 [2] - GigaDevice Semiconductor (02367) had a net outflow of -179 million, with a net outflow ratio of -31.12% and a closing price of 38.620 [2] - Zhaojin Mining (01818) recorded a net outflow of -162 million, with a net outflow ratio of -19.70% and a closing price of 29.840 [2] Net Inflow Ratio Rankings - GX Hengsheng Technology (02837) achieved a net inflow ratio of 89.26%, with a net inflow of 36.552 million and a closing price of 7.310 [3] - Far East Horizon (03360) had a net inflow ratio of 80.25%, with a net inflow of 27.178 million and a closing price of 7.140 [3] - Tuhu-W (09690) recorded a net inflow ratio of 67.29%, with a net inflow of 19.987 million and a closing price of 18.050 [3] Net Outflow Ratio Rankings - Huadian International Power (01071) had the highest net outflow ratio at -74.23%, with a net outflow of -23.262 million and a closing price of 4.400 [3] - CIMC Enric (03899) recorded a net outflow ratio of -63.04%, with a net outflow of -15.158 million and a closing price of 7.880 [3] - Weilu Group (01196) experienced a net outflow ratio of -57.66%, with a net outflow of -10.037 million and a closing price of 12.090 [3]

Core Insights - The company, Juzhi Biotechnology, has received approval for its recombinant type I α1 collagen protein lyophilized fiber, which is indicated for facial dermal tissue filling to correct dynamic wrinkles such as glabellar lines, forehead lines, and crow's feet [1][2]. Product Development - Juzhi Biotechnology has four recombinant collagen injection products under application, including liquid and solid formulations for facial wrinkles and gels for nasolabial folds and neck wrinkles [1]. - The company’s recombinant collagen gel for neck wrinkles has entered the priority approval channel, which is expected to expedite the approval process for its products [2]. Innovation and Patents - The company has received patent authorization for two innovative products: a recombinant type IV collagen composition for sensitive skin care and a fermented ginseng product aimed at cognitive impairment and memory improvement [2]. Financial Projections - Juzhi Biotechnology is a leader in the recombinant collagen sector in China, with projected net profits of 2.566 billion, 3.214 billion, and 4.046 billion yuan for 2025-2027, reflecting year-on-year growth rates of 24%, 25%, and 26% respectively [3]. - The latest closing price corresponds to a price-to-earnings ratio of 16, 12, and 10 for 2025-2027, maintaining a "buy" rating [3].

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by Juzi Bio marks a significant milestone as it is the first recombinant type I natural sequence collagen facial injection product in China, with potential for over 1 billion in sales in the long term [1] Group 1: Product Approval and Market Potential - Juzi Bio's recombinant type I collagen product is primarily aimed at facial dermal tissue filling to correct dynamic wrinkles, including forehead and crow's feet [1] - The product's long-term sales potential is estimated to exceed 1 billion, with a notable profit margin, referencing Jinbo Biotech's net profit margin of 45.66% in 1H25 [1] - The current market for injectable recombinant collagen is limited, with Jinbo Biotech focusing on recombinant type III humanized collagen products, which have shown significant revenue growth [1] Group 2: Brand Performance and Sales Growth - The Q3 performance of the 可复美 (Kefumei) brand shows a recovery in online sales, with GMV reaching 615 million and a year-on-year increase of 20% [2] - The brand's promotional activities, including collaborations with influencers, have contributed to restoring brand visibility and sales [2] - The company has expanded its international presence, with Kefumei products entering 13 Watsons stores in Singapore [2] Group 3: Financial Forecast and Valuation - The company maintains its net profit forecasts for 2025-2027 at 26.00 billion, 32.03 billion, and 38.12 billion, respectively, with corresponding EPS of 2.53, 3.11, and 3.71 [2] - The target price is set at 85.0 HKD, based on a 31x PE for 2025, reflecting the company's leading position in the medical aesthetics sector and resilient sales performance [2]

Core Viewpoint - The approval of the first injectable recombinant collagen product by the company marks a significant milestone in its product matrix, which now includes aesthetic injection products, post-surgery repair dressings, and functional skincare [1] Group 1: Product Approval and Market Potential - The newly approved recombinant type I α1 collagen lyophilized fiber is intended for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - The Chinese aesthetic injection market is projected to reach CNY 147 billion by 2027, with the injectable collagen segment expected to grow to CNY 16.8 billion, indicating high growth potential [2] - Currently, there are four approved facial injectable recombinant collagen products in China, including the company's product and others from Jinbo Biotech [2] Group 2: Competitive Landscape and Channel Advantages - The company's product competes with Jinbo Biotech's offerings, which also target the dermal layer for wrinkle filling, suggesting future competition in eye and facial anti-aging scenarios [2] - The company has a strong channel advantage through its established brand recognition and deep distribution network in the aesthetic market, which is expected to enhance the market potential of the new injectable products [2] Group 3: Future Product Pipeline - The company has two additional injectable collagen products in the approval stage, with expected approval timelines in December 2024 and August 2025, which will further enrich its aesthetic product matrix [3] - These upcoming products will cover a range of anti-aging scenarios from dynamic wrinkle improvement to overall skin texture enhancement [3] Group 4: Financial Outlook and Ratings - The company maintains a "Buy" rating with a target price of HKD 58.35, despite a projected decline in online sales for its brand, which may affect overall revenue growth [4] - The company's revenue growth forecast for 2025 has been adjusted down to 12%, with a long-term CAGR for its brand's revenue growth revised from 26% to 14.5% [4]